key: cord-1032555-y1posq7n
authors: Chen, Ruchong; Gao, Yi; Chen, Mu; Jian, Wenhua; Lei, Chunliang; Zheng, Jinping; Li, Shiyue
title: Impaired pulmonary function in discharged patients with COVID-19: More work ahead
date: 2020-06-25
journal: Eur Respir J
DOI: 10.1183/13993003.02194-2020
sha: e9a30a5ddcb19de7024937a30f970ea15a86dcb6
doc_id: 1032555
cord_uid: y1posq7n

Impairment of diffusion capacity is the most common abnormality in discharged patients with COVID-19. Both decreased alveolar volume and KCO contribute to the pathogenesis of impaired diffusion capacity. More work ahead for follow-up is needed.

We are grateful for the opportunity to respond to the letter by Dr. Nusair, whom we thank for his interest and thoughtful remarks about our study on the abnormal pulmonary function in COVID-19 patients [1] .

Diffusing capacity of the lung for carbon monoxide (DLCO) reflects the capacity of carbon monoxide (CO) transfer from the environment to the pulmonary capillary blood, which is the most clinically useful routine methodology to evaluate the function of the lung to exchange gas. KCO is the rate constant for CO uptake from alveolar gas, which is influenced mostly by the thickness and area of the alveolar capillary membrane, the volume of blood in capillaries supplying ventilated alveoli, and the concentration and properties of hemoglobin (Hb) in the alveolar capillaries blood. DLCO is mainly determined by KCO and the alveolar volume (VA).

Mathematically, KCO can be calculated as DLCO/VA under body temperature, ambient pressure, saturated with water vapor (BTPS) conditions [2] .

We agree with Dr. Nusair that it should be noted that DLCO/VA is not a simple ratio and in fact the relationship between lung volume and CO uptake is linearly and certainly less than 1:1 [3] . Recent studies have tended to use KCO instead of DLCO/VA, as DLCO/VA may be inferred that DLCO can be normalized for VA. The 2017 ERS/ATS standards for singlebreath carbon monoxide uptake in the lung recommends that the term of KCO is better way than DLCO/VA [2] . However, in practice, many pulmonary function test reports from different manufacturers still present with DLCO/VA but not KCO. Besides, in order for an easier and direct comparison with some previous studies on pulmonary function in patients with SARS [4, 5] , DLCO/VA was kept in our report. It is important to understand the interpretation of KCO and DLCO/VA, the term of KCO is recommended for more popular use in future.

Decreased KCO occurs in alveolar-capillary damage, microvascular pathology, or anemia.

Causes of low VA includes reduced alveolar expansion, alveolar damage or loss, or inspired gases maldistributed with airflow obstruction. When KCO turns normal, in the presence of a low DLCO it is associated with low VA. Because only the functional alveolar unities had been sampled thereby providing a biased picture toward more preserved areas of the lungs [3] .

Crucially, the same DLCO may occur with various combinations of KCO and VA, each suggesting different pathologies. It is difficult to interpret which is the predominant role because both decreased alveolar volume and KCO contribute to the pathogenesis of impaired diffusion capacity. DLCO gives an overall assessment of gas exchange for the lung, while the alveolar-capillary membrane diffusing capacity for carbon monoxide (DMCO) only dependents on molecular diffusion of the membranes. However, DMCO can be calculated using different equations but not unified yet, which is not a commonly used gas diffusing parameter [6] . to the systemic impaired microcirculatory function [7] . Acute pulmonary embolism has been reported during the clinical course [8] . Postmortem studies reported the vascular injury and thrombi in multiple organs [7, 9] . Ackermann et al [10] Our study showed that, similar as DLCO, DLCO/VA (represents the transfer factor of carbon monoxide) also showed an association with the disease severity: As the patients underwent more severe condition, mean value of DLCO/VA of predicted was lower. Since standard deviation value suggest that individual differences have effects on lung function, we had also provided the distribution of the DLCO/VA of predicted in patients with different severity. 42% of the subjects with severe pneumonia had a DLCO/VA of predicted less than 80%, while only 27% in the patients with pneumonia and 13% in patients with mild illness, respectively.

In previous follow-up studies of SARS, the impaired DLCO was defined as when DLCO was <80% of the predicted value irrespective of the KCO or the alveolar volume. In the follow-up studies of rehabilitating SARS patients ranging from 0.5-2 years, the impaired DLCO was the most common abnormality, accounting for 15.5% to 43.6% [11] [12] [13] . The mean of the DLCO/pred% ranged from 77.7% to 93.8% in the studies above with the longest follow up of 2 years. Our study showed a mean of DLCO/pred% for 78.2% at time of discharge but the data of follow up is not available yet. It is unclear how the impaired diffusion capacity change in survivors of COVID-19, as well as in the chest CT. In one study, where surviving SARS patients were seen 6 months after admission, 43(75.4%) of patients showed radiological abnormalities, including 62.8% had abnormal DLCO [11] . Thus, the lung function impairment findings are consistent with the CT images of SARS survivors showing persistent ground glass opacity, reticular opacities and traction bronchiectasis suggesting the fibrosis [14] .

Likewise, in discharged patients with COVID-19, Wang et al reported that 94% (66/70) of patients who were discharged from hospital at the end of the study still had mild to substantial residual lung abnormalities on their last CT scans [15] .

Our study was a pilot study which firstly described the impaired pulmonary function in patients with COVID-19 at time of discharge. Impairment of diffusion capacity is the most common abnormality followed by restrictive ventilatory defects. However, more work ahead for follow-up is needed to assess the longitudinal variation of these deficits.

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

ERS/ATS standards for single-breath carbon monoxide uptake in the lung

Incorporating Lung Diffusing Capacity for Carbon Monoxide in Clinical Decision Making in Chest Medicine

1-year pulmonary function and health status in survivors of severe acute respiratory syndrome

Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge

Dinh-Xuan AT. Standardisation and application of the single-breath determination of nitric oxide uptake in the lung

Endothelial cell infection and endotheliitis in COVID-19

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study